---
source_path: R2502C-PDF-ENG.md
pages: n/a-n/a
chunk_id: db4765322860d9b74e2530c3d9ca80e9836710f5
title: R2502C-PDF-ENG
---
# Max Drekker

Now it is facing another macro force: New GLP-1 receptor agonist drugs

such as Ozempic and Mounjaro are making weight loss and diabetes treatments easier and more eﬀective. As a result, diet companies and

some ﬁtness centers are facing declining demand for their traditional

products and services. Runyon is framing this development as an

opportunity, not just a threat. He believes that as people feel healthier

and more conﬁdent, they will be more inclined to join a gym or a

ﬁtness center that treats them right. And recognizing that as people lose

weight, they also lose muscle mass, SEB is developing special workouts,

virtual coaching, and customized nutrition programs for people taking

various GLP-1 medications. For instance, it is increasing cooperation

Copyright © 2025 Harvard Business School Publishing. All rights reserved.

15

This document is authorized for use only by Matt O'Donnell (matthew.od11@gmail.com). Copying or posting is an infringement of copyright. Please contact customerservice@harvardbusiness.org or 800-988-0886 for additional copies.
